A Review of the Current and Future Position for Johnson & Johnson in the Pharmaceutical Industry, Including a 1-6 Year Sales Forecasts.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c27462) has announced the addition of Pharmavitae 2005: Johnson & Johnson Global Analysis to their offering. This Analysis examines the current position and future outlook for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to Purchase Understand how J&Js mature product portfolio and the risk of generic competition will impact sales growth over the forecast period Benchmark J&Js performance against key rivals in the ethical pharmaceutical sector Learn why J&J must continue to focus on M&A and licensing to generate sales growth over the forecast period Topics Covered Addendum addendum n. an addition to a completed written document. Most commonly this is a proposed change or explanation (such as a list of goods to be included) in a contract, or some point that has been subject of negotiation after the contract was originally proposed by : CHAPTER 1 EXECUTIVE SUMMARY 5 Key findings Current positioning: competitive outlook 2004 Future performance: growth drivers and resistors 2005-10 Evolution in therapeutic focus: 2004-10 Key issues facing J&J: 2005 - 10 Strategic outlook CHAPTER 2 GLOBAL COMPANY STRATEGY Introduction to Johnson & Johnson Assessment of strategic position Strengths Weaknesses Opportunities Threats Therapeutic foci R&D productivity Development opportunities Organic growth Partnerships/licensing Mergers and acquisitions Geographical expansion Implications of financial position CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS Therapy area focus in 2004 Business development by therapy area Forecast revenue stream, 2005-10 Therapy area forecasts to 2010 CNS See Continuous net settlement. CNS See continuous net settlement (CNS). franchise Marketed products R&D compounds CNS portfolio sales forecasts and forecast revenue growth Oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. franchise Marketed products R&D compounds Oncology portfolio sales forecasts and forecast revenue growth Arthritis arthritis, painful inflammation of a joint or joints of the body, usually producing heat and redness. There are many kinds of arthritis. In its various forms, arthritis disables more people than any other chronic disorder. , immune & inflammatory franchise Marketed products R&D compounds AIID AIID Autoimmune and Inflammatory Disorders AIID Association des Infirmiers(ères) Intervenant(e)s en Diabétologie portfolio sales forecasts and forecast revenue growth Gastrointestinal gastrointestinal /gas·tro·in·tes·ti·nal/ (-in-tes´ti-n'l) pertaining to or communicating with the stomach and intestine. gas·tro·in·tes·ti·nal adj. Abbr. franchise Marketed products R&D compounds Gastrointestinal portfolio sales forecasts and forecast revenue growth Women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. franchise Marketed products R&D compounds Women's health portfolio sales forecasts and forecast revenue growth Infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. franchise Marketed products R&D compounds Infectious disease portfolio sales forecasts and forecast revenue growth HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. franchise Marketed products R&D compounds HIV portfolio sales forecasts and forecast revenue growth Other products Marketed products R&D compounds Other products sales forecasts and forecast revenue growth CHAPTER 4 CORPORATE DEVELOPMENT Financial position, 2003 - 2004 Profitability, 2000-2004 Revenue growth Cost structure Profitability Liquidity, 2000-2004 2004 performance benchmarking Business model clustering according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. 2004 cost ratios 2003 growth and investment momentum Key events shaping corporate activity, 2000-2004 Merger and acquisition activity Corporate alliances and deals CHAPTER 5 APPENDIX : SUPPORTING DATA Financial data Exchange rates Biogeneric threat Methodology for therapy area forecasting LIST OF TABLES LIST OF FIGURES For more information visit http://www.researchandmarkets.com/reports/c27462 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion